Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function

Fabian Frost, Tim Kacprowski, Malte Rühlemann, Maik Pietzner, Corinna Bang, Andre Franke, Matthias Nauck, Uwe Völker, Henry Völzke, Marcus Dörr, Jan Baumbach, Matthias Sendler, Christian Schulz, Julia Mayerle, Frank U Weiss, Georg Homuth, Markus M Lerch

INTRODUCTION

The human gut constitutes a habitat for the complex ecosystem which encompasses trillions of micro-organisms, together known as the intestinal microbiome. Bacterial cells represent the largest fraction of this biotope even outnumbering their human host by cell number. Jointly the gut microbiota carry out important metabolic functions, which are critical for the maintenance of human health. At the same time dysbiosis, a state of structural and functional microbiota disruption, can contribute to a variety of intestinal microbiome instability. Factors associated with the greatest long-term stability of the faecal microbiota composition are high initial microbial (alpha) diversity, female sex, high household income and preserved exocrine pancreatic function. The gut microbiome affects the emotional and mental health of the host, and thereby plays a role in the pathogenesis of diseases. Dysbiosis, a variant of the microbial ecosystem leading to increased pathogenicity and decreased healthy state, plays a role in the development of diseases ranging from obesity to diabetes mellitus and metabolic syndrome. Low alpha diversity, the disturbance of the microbiome composition, and increased susceptibility to dysbiosis-associated diseases were associated with the development of metabolic liver disease or diabetes mellitus. Therefore, long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.

ABSTRACT

Objective The intestinal microbiome affects the prevalence and pathophysiology of a variety of diseases ranging from inflammation to cancer. A reduced taxonomic or functional diversity of the microbiome was often observed in association with poorer health outcomes or disease in general. Conversely, factors or manifest diseases that determine the long-term stability or instability of the microbiome are largely unknown. We aimed to identify disease-relevant phenotypes associated with faecal microbiota (in-)stability.

Results The overall microbiome landscape remained remarkably stable over time. The greatest microbiome instability was associated with factors contributing to metabolic syndrome such as fatty liver disease and diabetes mellitus. These, in turn, were associated with an increase in facultative pathogens such as Enterobacteriaceae or Escherichia/Shigella. Greatest stability of the microbiome was determined by higher initial alpha diversity, female sex, high household income and preserved exocrine pancreatic function. Participants who newly developed fatty liver disease or diabetes during the 5-year follow-up already displayed significant microbiota changes at study entry when the diseases were absent.

Conclusion This study identifies distinct components of metabolic liver disease to be associated with instability of the intestinal microbiome, increased abundance of facultative pathogens and thus greater susceptibility toward dysbiosis-associated diseases.

Downloaded from http://gut.bmj.com/ on September 21, 2022 by guest. Protected by copyright.
Significance of this study

How might it impact on clinical practice in the foreseeable future?

- Individuals suffering from metabolic liver disease or metabolic syndrome may exhibit greater susceptibility towards dysbiosis-associated disorders.
- Whether attempts to maintain or restore the gut microbiome community structure can positively affect the onset and course of metabolic liver disease needs to be investigated in intervention trials.

More environmental changes such as permanent shifts in geographic location, however, may cause enduring gut microbiota alterations. Ultimately, over time each individual faces numerous life events which will cumulatively shape the individual gut microbiota profiles. Previous investigations which tried to determine the specific changes occurring in the gut microbiota during adulthood mostly relied on cross-sectional data. This approach can be problematic as people of different ages have often been subjected to very different environmental conditions in the early years of their lives, which is a period of particular sensibility for the initial gut microbiota constitution. Moreover, cross-sectional analyses cannot determine whether and how the presence of an overt disease subsequently affects the microbiota composition and stability. Intraindividual comparisons using paired long-term follow-up data are therefore necessary to determine the contribution of different phenotypic factors to the gut microbiome changes over time. We therefore investigated intestinal microbiota profiles by 16S rRNA gene sequencing in 2564 paired faecal samples from 1282 participants of the Study of Health in Pomerania (SHIP), which were collected at two time points with a 5-year interval (SHIP-2 and SHIP-3, respectively) in this longitudinal cohort study (figure 1).

METHODS

Study participants

SHIP is a longitudinal cohort study located in Northeast Germany. It was designed to determine the incidence and prevalence of subclinical disorders, clinical disease and their risk factors. The population-based sample was drawn in 1996 from a population of 213 057 using a two-stage stratified cluster approach including only individuals aged 20–79 years. The net sample included 6265 subjects of which 4308 participated in the study. Follow-up investigations are scheduled in 5-year intervals and have already been performed from 2002 to 2006 (SHIP-1, n=3300), 2008–2012 (SHIP-2, n=2333) and 2014–2016 (SHIP-3, n=1718). Faecal samples for microbiota determination were collected at SHIP-2 and SHIP-3. Paired faecal microbiota data at both study time points were available for 1366 individuals. Of these, 84 datasets were removed due to intake of antibiotics at the time of sample collection, a history of gastrointestinal cancer, liver cirrhosis or missing data on a history of disorders including metabolic liver disease. The gut microbiota structure is not static over time but subject to continuous adaptive changes. The high interpersonal gut microbiota variation at a very young age decreases substantially until adulthood when the gut microbiome becomes more stable. But even afterwards, marked alterations as a response to environmental stimuli, for example, changes in diet, are possible but can still be largely reversible if the trigger is discontinued. Other environmental changes such as permanent shifts in geographic location, however, may cause enduring gut microbiota alterations. Ultimately, over time each individual faces numerous life events which will cumulatively shape the individual gut microbiota profiles. Previous investigations which tried to determine the specific changes occurring in the gut microbiota during adulthood mostly relied on cross-sectional data. This approach can be problematic as people of different ages have often been subjected to very different environmental conditions in the early years of their lives, which is a period of particular sensibility for the initial gut microbiota constitution. Moreover, cross-sectional analyses cannot determine whether and how the presence of an overt disease subsequently affects the microbiota composition and stability. Intraindividual comparisons using paired long-term follow-up data are therefore necessary to determine the contribution of different phenotypic factors to the gut microbiome changes over time. We therefore investigated intestinal microbiota profiles by 16S rRNA gene sequencing in 2564 paired faecal samples from 1282 participants of the Study of Health in Pomerania (SHIP), which were collected at two time points with a 5-year interval (SHIP-2 and SHIP-3, respectively) in this longitudinal cohort study (figure 1).

SEQUENCING

Interviews
Anthropometrics
Laboratory tests
Pancreatic elastase
Liver and carotid ultrasound

Figure 1  Scheme of study design. Paired microbiota profiles from Study of Health in Pomerania (SHIP)-2 and SHIP-3 participants (n=1282 at each time point) and corresponding SHIP-2 phenotype data were included into the analysis.

16S rRNA gene sequencing

Sequencing was performed as described before in detail. In brief, faecal samples were collected by the study participants at home, stored in a tube containing stabilising DNA buffer and then transported to our laboratory by the participants or courier. After DNA from faecal samples was isolated (PSP Spin Stool DNA Kit; Stratec Biomedical AG, Birkenfeld, Germany), it was stored at −20°C until analysis by 16S rRNA gene sequencing of the V1–V2 region on a MiSeq platform (Illumina, San Diego, California, USA).

Assignment of taxonomic annotation and predicted metagenomics

More details on taxonomy assignment and predicted metagenomics are given in the online supplemental methods. In brief, the open-source software package DADA2 (V1.10) was used for amplicon data processing which enables a single-nucleotide resolution of amplicons. The functional genomic potential of the faecal microbiota were predicted with PICRUSt2. All samples were normalised to 10 000 16S rRNA gene read counts for analysis.

Metabolomic measurements

In a subsample of 911 SHIP-2 individuals plasma metabolites were determined using the AbsoluteIDQ p180 Kit (BIOCRATES LifeSciences AG, Innsbruck, Austria) on an AB SCIEX 5500 QTrap mass spectrometer (AB SCIEX, Darmstadt, Germany) with electrospray ionisation combined with a HPLC system (Agilent 1260 Infinity Binary LC, Santa Clara, California, USA). Following quality control and data processing, 177 metabolites were available for statistical analyses.
Phenotype data

Determination of laboratory parameters (alanine aminotransferase (ALT), creatinine, high-density lipoprotein (HDL), low-density lipoprotein (LDL), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), thyroid-stimulating hormone (TSH)) was performed on a Dimension VISTA platform (Siemens Healthcare Diagnostics, Eschborn, Germany). Glycated haemoglobin (HbA1c) concentrations were determined using a
high-performance liquid chromatography (Bio-Rad Diamat, Munich, Germany). Estimation of glomerular filtration rate (eGFR) was done using the CKD-EPI equation.\textsuperscript{18} NT-proBNP measurements were treated as missing in case of eGFR \( \leq 30 \) \( \text{mL/min} \) due to possible accumulation. The trait diabetes mellitus was assigned to all individuals with a positive history of diabetes mellitus in combination with a history of current treatment (diet, medication or insulin), a random blood glucose \( \geq 11.1 \text{mmol/L} \) or an HbA1c \( \geq 6.5\% \). Alcohol consumption was estimated in grams alcohol per day, by counting the number of alcoholic beverages that had been consumed on average per day over the last 30 days and calculation of its average alcoholic content. Smoking was quantified as on average smoked cigarettes per day. Fatty liver disease (FLD) was determined based on ultrasound findings in case of hyperechoic liver tissue (in the absence of a history of liver cirrhosis) using a high-resolution device (Vivid i, GE Healthcare, Chicago, Illinois, USA) in B mode in combination with serum ALT levels belonging to the upper 25\% of the investigated population. The trait arterial hypertension was assigned in case of antihypertensive medication or a systolic blood pressure \( \geq 140 \text{mm Hg} \) or a diastolic blood pressure \( \geq 90 \text{mm Hg} \) in the third of consecutive measurements. Carotid intima–media thickness was measured bilaterally (Vivid i) and thereafter the average of both sides calculated. Manifest atherosclerotic disease (as opposed to carotid intima–media thickness) was assigned if the participants had a history of myocardial infarction and/or stroke. Hypothyroidism was assumed when TSH was \( \geq 4 \) mIU/L in case of antihypothalamic hormone replacement therapy. A food frequency score, net household income) or nominal data (arterial hypertension, diabetes mellitus, dyslipidaemia, FLD, female sex, hypothyroidism, manifest atherosclerotic disease, proton pump inhibitor usage), respectively (‘corr.test’ function, \textit{stats}). Afterwards, the significance of those factors identified to correlate with microbiota (in-)stability was confirmed by performing a linear regression model including possible confounding factors as stated in the online supplemental table S4. The associations of incident diseases at SHIP-3 with SHIP-2 and SHIP-3 microbiota profiles were determined by performing permutational analysis of variance (\textit{vegan} function ‘adonis’; 1000 permutations). For linear regression analysis, microbiota data were cleared from zeros (treated as missing), log-transformed and standardised. Metabolome data were also log-transformed and standardised before linear regression analysis. Included covariates for regression models are listed in the online supplemental tables S4–S11 of the respective analyses. All p-values derived from comparisons of PCo scores, phenotype–microbiota associations, taxon comparisons of relative abundance, presence–absence, genomic pathway or alpha diversity data were corrected for multiple testing by the method of Benjamini-Hochberg (\textit{p.adjust} function, \textit{stats}) and thereafter called q-values. P-values or q-values \( <0.05 \) were considered significant. All p-values and q-values were rounded to three significant digits.

\textbf{Data analysis}

All statistical analyses were performed using ‘R’ (v3.6.3).\textsuperscript{21} Alpha diversity scores were determined with the ‘diversity’ function (\textit{vegan}).\textsuperscript{22} The Bray-Curtis (BC) dissimilarity, Euclidean and Jaccard distance were calculated using the function ‘vegdist’ (\textit{vegan}). Principal coordinate analysis (PCoA) was carried out by the ‘cmdscale’ function (\textit{vegan}). The emergence of negative eigenvalues during PCoA was avoided by square root transformation of the BC dissimilarity prior to the ordination. To test for significant differences of the PCo1–PCo5 scores between SHIP-2 and SHIP-3, paired two-sided Wilcoxon-signed rank tests were performed. For permutational analysis of variance, the function ‘adonis’ (\textit{vegan}; 1000 permutations) was used. Comparison of the relative abundance data between SHIP-2 and SHIP-3 of all taxa that were present in at least 10\% of all SHIP-2 samples and with a mean abundance of at least 0.1\% was done using the paired two-sided Wilcoxon-signed rank tests. Comparison of the taxon presence–absence profiles between SHIP-2 and SHIP-3 of all taxa that were present in at least 10\% but less than 80\% of all samples was performed using McNemar’s test (‘mcnemar.exact’ function, \textit{exact2x2}). Differences in genomic pathways between SHIP-2 and SHIP-3 were evaluated using the paired two-sided Wilcoxon-signed rank tests. Only pathways with a presence of at least 25\% of samples at SHIP-2 were considered for this analysis. Alpha diversity scores of SHIP-2 and SHIP-3 samples were compared using the paired two-sided Wilcoxon-signed rank test. Assessment of association between phenotypic factors at SHIP-2 and faecal microbiota changes toward SHIP-3 (microbial (in-)stability) expressed as log-transformed BC dissimilarity, Euclidean or Jaccard distance was performed as follows: metric variables were cleaned from outliers which were more than 3 SD away from the mean. Metric variables without zeros (eg, HbA1c) were log-transformed, whereas square root transformation was performed in case of present zeros (cigarettes per day or alcohol consumption). Afterwards, Pearson, Spearman or point biserial correlations were calculated for metric (age, alcohol, body mass index (BMI), carotid intima–media thickness, HbA1c, LDL/HDL ratio, eGFR, pancreatic elastase, number of household members, NT-proBNP, species richness (N0), smoking, TSH), ordinal (food frequency score, net household income) or nominal data (arterial hypertension, diabetes mellitus, dyslipidaemia, FLD, female sex, hypothyroidism, manifest atherosclerotic disease, proton pump inhibitor usage), respectively (‘corr.test’ function, \textit{stats}). Afterwards, the significance of those factors identified to correlate with microbiota (in-)stability was confirmed by performing a linear regression model including possible confounding factors as stated in the online supplemental table S4. The associations of incident diseases at SHIP-3 with SHIP-2 and SHIP-3 microbiota profiles were determined by performing permutational analysis of variance (\textit{vegan} function ‘adonis’; 1000 permutations). For linear regression analysis, microbiota data were cleared from zeros (treated as missing), log-transformed and standardised. Metabolome data were also log-transformed and standardised before linear regression analysis. Included covariates for regression models are listed in the online supplemental tables S4–S11 of the respective analyses. All p-values derived from comparisons of PCo scores, phenotype–microbiota associations, taxon comparisons of relative abundance, presence–absence, genomic pathway or alpha diversity data were corrected for multiple testing by the method of Benjamini-Hochberg (\textit{p.adjust} function, \textit{stats}) and thereafter called q-values. P-values or q-values \( <0.05 \) were considered significant. All p-values and q-values were rounded to three significant digits.

\textbf{Data availability}

All microbiome and phenotype data were obtained from the SHIP data management unit and can be applied for online through a data access application form (https://www.fvcmed.uni-greifswald.de/dd_service/data_use_intro.php).

\textbf{Patient and public involvement statement}

SHIP is a regionally confined epidemiological study that regularly informs participants about current investigations and recent findings by newsletter, YouTube videos (eg, https://www.youtube.com/watch?v=t7C8dGNJ_rk) and its website (https://www2.medizin.uni-greifswald.de/cm/ship/). Participates serve on the advisory board of the SHIP study and SHIP organises public hearings for question and answer sessions and for input from the public regarding its research focus.

\textbf{RESULTS}

\textbf{Overall faecal microbiota community profile}

The overall faecal microbiota community profile was remarkably stable over time with \textit{Bacteroides}, \textit{Prevotella} and \textit{Faecalibacterium
reducing the three most abundant taxa at follow-up (figure 2A).

To further investigate the temporal stability of the faecal microbiota, an analysis of beta diversity, which provides information how microbiota communities or samples differ from each other, was carried out using PCoA dissimilarity. Subsequent PCoA based on BC including all paired 2564 baseline and follow-up samples confirmed a largely stable faecal microbiota composition between SHIP-2 and SHIP-3 (figure 2B). However, detailed analysis of the PCo scores revealed significant structural microbiota changes (figure 2C) indicating specific microbiota shifts in some individuals.

Determination of changes in taxon abundance and predicted metagenomics from baseline to follow-up

A total of 18 taxa were identified with significant abundance changes at follow-up compared with baseline (figure 2D and online supplemental table S1). A comparison between baseline and follow-up samples based on presence–absence data revealed 16 taxa with significantly altered presence profiles (figure 2E and online supplemental table S2). No major changes were found in alpha diversity, which describe the taxon variation within a sample, although median N0 was slightly lower at follow-up (q=0.012) compared with baseline (figure 2F). Corresponding to the changes in several taxa, alterations in 16 predicted metagenomic pathways with significantly (q<0.05) increased or decreased abundance or no significant alteration. D/U/A, degradation, utilisation, assimilation; GoPMaE, generation of precursor metabolites and energy.

Determination of phenotypic factors associated with stability or instability of the faecal microbiome

Several mostly cross-sectional studies have been conducted to identify the factors that contribute to the gut microbiota variation showing associations with age, sex, exocrine pancreatic function, obesity, diabetes mellitus, FLD, diet or medication among other factors.7–14 24–27 We therefore investigated whether these and other phenotypic factors (table 1) were also associated either positively or negatively to longitudinal faecal microbiota changes from baseline to follow-up (expressed as beta diversity). As a result, numerous host characteristics were found to be associated with either increased or decreased faecal microbiota stability (figure 4). A positive correlation with changes in the faecal microbiome (BC) over time was found for FLD (q=0.006), diabetes mellitus (q=0.007) and the level of glycaemic control (HbA1c, q=0.014). An increase in BMI exhibited a smaller positive but non-significant (q=0.067) association. Several other phenotypic traits were predictive of faecal microbiota stability (negative association to BC), among them high initial microbial diversity (N0 at SHIP-2, q<0.001), female

| Table 1 | Distribution of phenotype variables at SHIP-2 |
|-----------------|-----------------|-----------------|-----------------|
| **Continuous variables** | **Mean (±SD)** | **Median (first–third quartile)** | **Missing data (%)** |
| Age (years) | 55.8 (±12.3) | 56.0 (46.0–65.0) | 0.0 |
| Alcohol (g/day) | 9.1 (±12.7) | 4.3 (1.2–11.5) | 2.2 |
| BMI (kg/m²) | 28.0 (±4.8) | 27.4 (24.6–30.7) | 0.1 |
| Cardiot intima–media thickness (mm) | 0.6 (±0.1) | 0.6 (0.5–0.7) | 1.2 |
| Exocrine pancreatic function (pancreatic elastase, µg/g stool) | 460.3 (±166.8) | 481.0 (346.0–585.0) | 0.5 |
| Glycemic control (HbA1c, %) | 5.4 (±0.8) | 5.3 (5.0–5.7) | 0.1 |
| Cardiac function (NT-proBNP, pg/mL) | 112.6 (±174.4) | 66.5 (36.0–120.8) | 3.1 |
| Household net income (class) | 4.9 (±2.0) | 5.0 (4.0–6.0) | 1.5 |
| LD/L/HDL ratio | 2.5 (±0.9) | 2.3 (1.8–3.1) | 0.2 |
| No of household members | 2.2 (±0.9) | 2.0 (2.0–3.0) | 0.0 |
| Renal function (eGFR, mL/min) | 87.6 (±17.2) | 88.5 (76.3–99.9) | 0.1 |
| Smoking (cigarettes/day) | 2.1 (±5.5) | 0.0 (0.0–0.0) | 0.0 |
| Species richness (NI) | 248.3 (±63.4) | 245.0 (205.0–287.0) | 0.0 |
| Thyroid function (TSH, mU/L) | 1.2 (±1.0) | 1.0 (0.7–1.5) | 0.3 |

All variables are in alphabetical order. All values are rounded to one decimal place. BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SHIP, Study of Health in Pomerania; TSH, thyroid-stimulating hormone.

Determination of changes in taxon abundance and predicted metagenomics pathways with significantly (q<0.05) increased or decreased abundance or no significant alteration. D/U/A, degradation, utilisation, assimilation; GoPMaE, generation of precursor metabolites and energy.

**Figure 3** Sankey plot displays the proportions of predicted metagenomic pathways with significantly (q<0.05) increased or decreased abundance or no significant alteration. D/U/A, degradation, utilisation, assimilation; GoPMaE, generation of precursor metabolites and energy.
dase-4 (DPP-4) inhibitors in case of the traits diabetes mellitus and glycaemic control confirmed the significance of the aforementioned associations. Using Jaccard distance, we investigated whether the microbiota profiles of those individuals who had newly developed any of these diseases in SHIP-3 differed from those who remained disease free at both time points. Individuals newly classified with FLD or diabetes mellitus at SHIP-3 exhibited a significantly different gut microbiome composition compared with participants without the respective disorder (p<0.001 and p=0.008, respectively). This association could already be found at SHIP-2 before FLD or diabetes mellitus had become apparent (p=0.009 and p=0.034). Incident hypertension (p=0.003) also exhibited a significant link to the gut microbiome at SHIP-3, but not in SHIP-2. No significant link to the faecal microbiome was found for incident cases of manifest atherosclerosis, dyslipidaemia or hypothyroidism. This indicates that participants who newly developed diabetes mellitus or FLD during the 5-year follow-up already displayed significant microbiota composition changes at study entry when the diseases were still absent.

To further explore these changes in individuals with incident FLD or diabetes mellitus, we performed linear regression analysis adjusting for different possible confounding factors (online supplemental tables S7–11). Individuals with incident FLD at SHIP-3 already presented with changes in Clostridium XIVa, Clostridium XIVb, Collinsella and Oscillo bacter as well as 15 plasma metabolite levels prior to their diagnosis at SHIP-2 (figure 5B,C and online supplemental tables S7 and S8). Clostridium XIVa did not only associate with increased plasma levels of various phosphatidylcholines but also exhibited a strong association with an increase of gut microbial pathways for fatty acid biosynthesis which was independent of the individual's diet (food frequency score) and BMI (online supplemental table S9). The gut microbiota and plasma metabolome alterations at SHIP-2 in individuals with incident diabetes mellitus at SHIP-3 were of lesser extent (figure 5D,E and online supplemental tables S10 and S11).

DISCUSSION

In the present study, we performed a long-term intestinal microbiota follow-up of 1282 individuals to identify the phenotype factors that (de-)stabilise the microbiome. Overall, the global faecal microbiota profile of the whole population showed a largely stable composition over time. Levels of alpha diversity remained stable except for a small reduction in N0. However, levels of facultative pathogenic taxa such as Enterobacteriaceae, Escherichia/Shigella and Citrobacter were consistently increased at follow-up after 5 years. This finding was pronounced in subjects carrying a phenotype associated with less stable microbiota composition. Members of the family of Enterobacteriaceae, especially Escherichia coli, represent the most common pathogens found in either blood or bile from individuals suffering from acute cholecystitis or cholangitis, abdominal

Figure 4. Contribution of phenotypic factors to faecal microbiome changes. Shown are the correlations between different phenotypic factors at SHIP-2 and global changes in the faecal microbiome from SHIP-2 to SHIP-3. Large positive associations indicate greater variation or instability in the faecal microbiome if the respective factor is distinctly elevated (continuous variables) or positive (binary variables). On the other hand, large negative associations suggest stability of the faecal microbiome. *Indicates significant associations (q<0.05). BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SHIP, Study of Health in Pomerania; TSH, thyroid-stimulating hormone.

sex (q=0.015), high net household income (q=0.014) and preserved exocrine pancreatic function (q=0.039). Additional regression analyses with adjustment for possible confounding factors (online supplemental table S4A), including the oral antidiabetic medications metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in case of the traits diabetes mellitus and glycaemic control confirmed the significance of the aforementioned associations. Using Jaccard distance, we investigated whether the microbiota profiles of those individuals who had newly developed any of these diseases in SHIP-3 differed from those who remained disease free at both time points. Individuals newly classified with FLD or diabetes mellitus at SHIP-3 exhibited a significantly different gut microbiome composition compared with participants without the respective disorder (p<0.001 and p=0.008, respectively). This association could already be found at SHIP-2 before FLD or diabetes mellitus had become apparent (p=0.009 and p=0.034). Incident hypertension (p=0.003) also exhibited a significant link to the gut microbiome at SHIP-3, but not in SHIP-2. No significant link to the faecal microbiome was found for incident cases of manifest atherosclerosis, dyslipidaemia or hypothyroidism. This indicates that participants who newly developed diabetes mellitus or FLD during the 5-year follow-up already displayed significant microbiota composition changes at study entry when the diseases were still absent.

To further explore these changes in individuals with incident FLD or diabetes mellitus, we performed linear regression analysis adjusting for different possible confounding factors (online supplemental tables S7–11). Individuals with incident FLD at SHIP-3 already presented with changes in Clostridium XIVa, Clostridium XIVb, Collinsella and Oscillo bacter as well as 15 plasma metabolite levels prior to their diagnosis at SHIP-2 (figure 5B,C and online supplemental tables S7 and S8). Clostridium XIVa did not only associate with increased plasma levels of various phosphatidylcholines but also exhibited a strong association with an increase of gut microbial pathways for fatty acid biosynthesis which was independent of the individual's diet (food frequency score) and BMI (online supplemental table S9). The gut microbiota and plasma metabolome alterations at SHIP-2 in individuals with incident diabetes mellitus at SHIP-3 were of lesser extent (figure 5D,E and online supplemental tables S10 and S11).

DISCUSSION

In the present study, we performed a long-term intestinal microbiota follow-up of 1282 individuals to identify the phenotype factors that (de-)stabilise the microbiome. Overall, the global faecal microbiota profile of the whole population showed a largely stable composition over time. Levels of alpha diversity remained stable except for a small reduction in N0. However, levels of facultative pathogenic taxa such as Enterobacteriaceae, Escherichia/Shigella and Citrobacter were consistently increased at follow-up after 5 years. This finding was pronounced in subjects carrying a phenotype associated with less stable microbiota composition. Members of the family of Enterobacteriaceae, especially Escherichia coli, represent the most common pathogens found in either blood or bile from individuals suffering from acute cholecystitis or cholangitis, abdominal
Gut microbiota abscesses (eg, liver abscesses) or urinary tract infections. Similarly *Citrobacter*, another member of *Enterobacteriaceae*, has been identified in urinary tract infections or intra-abdominal abscesses. The order *Enterobacterales*, which comprises the aforementioned facultative pathogens, has also been linked to increased intestinal permeability in humans. Therefore, greater microbiota instability with increased abundance of these potential pathogens may have harmful consequences for its human hosts by increasing the risk for localised or systemic infections. Moreover, at follow-up the predicted microbial pathways for LPS biosynthesis were increased by 27%. This increase was again pronounced in subjects with less stable faecal microbiota composition, for example, diabetics. LPS triggers the production of proinflammatory cytokines and can contribute to the development of FLD and diabetes mellitus. Hence, the microbial instability may predispose to further increases in LPS secretion activity which in turn can aggravate the metabolic disorders in a vicious circle.

A further, probably disadvantageous, faecal microbiota alteration was a reduction in the amount of *Bifidobacteria* carriers and the predicted genetic potential for bifidobacterial lactate production which could not be attributed to other phenotypic factors. *Bifidobacteria* have been reported to stabilise the gut barrier by reducing its permeability for inflammatory bacterial molecules such as LPS and to alleviate LPS-associated inflammation in the liver.
The individual extent of the faecal microbiota variation between SHIP-2 and SHIP-3 was variable. Disorders contributing to metabolic syndrome, metabolic liver disease and diabetes mellitus were associated with faecal microbiota instability. In our study, the association of diabetes mellitus with faecal microbiota variation could not be explained by oral antidiabetic medication such as metformin or DPP-4 inhibitors, both of which have previously been shown to be independently associated with composition changes of the gut microbiome.\(^{28, 29}\) When analysing changes in presence/absence patterns, we also found PPI usage to be linked to gut microbiota instability over time, which supports the finding of gut microbiota changes in PPI usage from a previous cross-sectional study.\(^{42}\) Of note, other conditions such as atherosclerosis, cardiac function, thyroid dysfunction or renal impairment had no significant impact. Participants’ older age was not associated with faecal microbiota instability. This suggests that as long as metabolic disease is absent, even at higher age, the gut microbiome may remain largely stable and resilient to perturbations.

On the other hand, several factors which were related to greater microbiota stability could be identified. The strongest negative association was found for alpha diversity at study entry, implying a microbiome stabilising effect. Diverse communities are less prone to the introduction of foreign species because of a greater coverage of ecological niches.\(^{43}\) A prominent example of how low microbial diversity can negatively affect the gut microbial integrity is \textit{Clostridium difficile}, for which in vitro studies have shown an increased growth in dysbiotic microbiota with low diversity.\(^{44}\) In humans, this situation typically occurs after antibiotic administration, a risk factor for \textit{Clostridium difficile}-associated colitis. A further protective factor of the faecal microbiome stability was preserved exocrine pancreatic function. Exocrine pancreatic function has already been shown to be the most important host factor regulating the faecal microbiota composition in a given population,\(^{45}\) which now includes a prominent role in determining long-term stability of the microbiome. This relationship may be explained by changes in the intestinal chyme and nutrient supply, due to maldigestion when pancreatic enzyme activity is reduced or due to impaired secretion of pancreatic antimicrobial peptides.\(^{45}\) The increasing faecal microbiota stability seen in individuals with higher socioeconomic status (net income) may be mediated by a reduced prevalence of disease in general, an increased utilisation of health preventive measures and/ or a healthier lifestyle.

Interestingly, individuals who newly developed FLD (and to a lesser degree also diabetes mellitus) at SHIP-3 already displayed significant faecal microbiota and plasma metabolome alterations at SHIP-2 when the respective diseases were absent. \textit{Clostridium XIVa}, which was increased in these individuals, also associated with an increased expression of those microbial pathways necessary for biosynthesis of saturated and unsaturated fatty acids, some of which have been described to promote hepatic lipogenesis\(^{46, 47}\), or are correlated to increased hepatic lipogenesis.\(^{48}\) Therefore, fatty acids synthesised by \textit{Clostridium XIVa} may increase hepatic accumulation of lipids, thus contributing to the development of FLD toward SHIP-3. Whether \textit{Clostridium XIVa} could serve as a treatment target for prebiotic or probiotic therapy to reduce the incidence of FLD needs to be determined in future interventional trials.

The advantage of this investigation is the usage of longitudinal microbiome data using paired samples at two time points to overcome the limitations of cross-sectional investigations. Moreover, the extensive phenotype database of the SHIP study allowed to identify critical host factors for faecal microbiota stability. A disadvantage of the study is the use of population-based data. Only the faecal microbiota relationship with conditions or states that are frequent enough to generate sufficient statistical power can be analysed in population-based cohorts, whereas estimation of the effect of less common or rare disorders on microbiota stability and composition requires disease-specific patient cohorts.\(^{49}\)

Here we present results from a large-scale faecal microbiota follow-up study over 5 years. With ageing, the amount of facultative pathogenic bacteria increased. However, ageing itself was not a predictor of faecal microbiota changes, whereas metabolic disorders were. Why some components of metabolic syndrome such as diabetes mellitus and FLD have a greater association than others with faecal microbiota instability and whether this is due to associated changes in gut immunology or variations in intraluminal nutrient supply needs to be investigated in human interventional trials, in which the respective disease process can actually be reversed. The association of increased instability of microbiota composition over time with metabolic syndrome is clearly suggestive of a direct causality. The observation, however, that participants who newly developed diabetes mellitus or FLD at the later time point, but 5 years earlier had no detectable manifestation of the disease, while already displaying significant changes in microbiota composition, clearly indicates that the relationship is more complex. On the other hand, a greater diversity of the intestinal microbiome, female sex and preserved exocrine pancreatic function were found to promote a greater long-term stability of the faecal microbiome and may therefore convey greater resilience against common, dysbiosis-associated disorders.

### Author affiliations
1. Department of Medicine A, University Medicine Greifswald, Greifswald, Germany
2. Chair of Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Technical University of Munich, Freising-Weihenstephan, Germany
3. Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany
4. Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany
5. DZHK (German Centre for Cardiovascular Research), partner site, Greifswald, Germany
6. Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany
7. Institute for Community Medicine, University of Greifswald, Greifswald, Germany
8. Department of Internal Medicine B, University of Greifswald, Greifswald, Germany
9. Department of Medicine II, University Hospital, LMU Munich, Munich, Germany

### Author contributions to the manuscript:

### Funding
This work was supported by the PePPP Project (ESF/14-BM-AS5_0045/16), the EnErGie/P2 Project (ESF/14-BM-AS5-0008/18) and the RESPONSE project (BMBF grant number 03ZZ20921E). SHIP is part of the Research Network Community Medicine of the University Medicine Greifswald which is supported by the German Federal State of Mecklenburg-West Pomerania.

### Competing interests
None declared.

### Patient consent for publication
Not required.

### Ethics approval
This study was approved by the local institutional review board, University Medicine Greifswald, Germany, registration numbers BB 39/08 and BB 122/13.

### Provenance and peer review
Not commissioned; externally peer reviewed.

### Data availability statement
Data may be obtained from a third party and are not publicly available. All microbiome and phenotype data were obtained from the SHIP data management unit and can be applied for online through a data access application form (https://www.fcm.med.uni-greifswald.de/dd_service/data_use_intro.php).
Supplemental material

This content has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Fabian Frost http://orcid.org/0000-0002-1502-8888
Malte Rücklemann http://orcid.org/0000-0002-0685-0052
Corinna Bang http://orcid.org/0000-0001-6814-6151
Andre Franke http://orcid.org/0000-0003-5390-5811
Julia Mayerle http://orcid.org/0000-0002-3666-6459
Markus M Lerch http://orcid.org/0000-0002-9643-8263

REFERENCES
